Table 2. Disease status and response after addition of Rapa + HCQ to metronomic chemotherapy.

Patient #	Tumor type	Performance status	Previous therapy after initial treatment failure	Control metronomic chemotherapy	Control treatment duration (months)	Response to control metronomic chemotherapy	Best response to Rapa + HCQ salvage chemotherapy	Evaluation method	Treatment duration (months)	Current status
1	Prostate ca with bone meta	1	Hormone therapy	Cyproterone 1# bid Docetaxel 40 mg q2wk	4	PD	SD	PSA > 50% decline	6	A
2	Prostate ca with bone meta	1	Hormone therapy	Cyproterone 1# bid Docetaxel 40 mg q2wk	2	PD	SD	PSA > 50%	3	A
3	Prostate ca with LN, bone meta	1	Hormone therapy	Cyproterone 1# bid Docetaxel 40 mg q2wk	3	SD	SD	PSA > 50% decline	3	A
4	Prostate ca with LN meta	0	Hormone therapy	Cyproterone 1# bid Docetaxel 40 mg q2wk	3	SD	PR	RECIST	3	A
5	Bladder ca with lung meta	1	—	Carboplatin 150 mg+ Gemcitabine 1400 mg q2wk	4	PD	SD	RECIST	8	A
6	Bladder ca with liver meta	1	Cisplatin 50 mg/m2; D1 +gemcitabine 1000 mg/m2 D, 8 q3w	Carboplatin 150 mg+ Gemcitabine 1400 mg q2wk	3	PD	PR	RECIST+ CFR 21.1 decline > 50%	3	A
7	Bladder ca with neck LN meta	0	—	Carboplatin 150 mg+ Gemcitabine 1400 mg q2wk	4	PD	PD	RECIST	3	A
8	Bladder ca with lung meta	1	—	Carboplatin 150 mg+ Gemcitabine 1400 mg q2wk	4	SD	PR	RECIST	8	D
9	Lung ca, adenocarcinoma with brain, pleural meta	1	TKI, RT, Cisplatin+ Pemetrexed	Vinorelbine 30 mg p.o. weekly, Docetaxel 40 mg q2wk	6	PD	PR	RECIST+ CEA decline > 50%	7	A
10	Lung ca, squamous carcinoma with pleural effusion	1	RT, Cisplatin+ Gemcitabine	Vinorelbine 30 mg p.o. weekly, Docetaxel 40 mg q2wk	3	PD	SD	RECIST	3	A
11	Lung ca, adenocarcinoma with multiple meta	1	TKI, RT, Cisplatin+ Pemetrexed	Vinorelbine 30 mg p.o. weekly, Docetaxel 40 mg q2wk	4	PD	SD	RECIST+ CEA decline > 50%	8	A
12	Lung ca, adenocarcinoma with multiple meta	0	TKI, Cisplatin+ Pemetrexed	Vinorelbine 30 mg p.o. weekly, Docetaxel 40 mg q2wk	2	PD	SD	RECIST	4	A
13	Rectal ca with peritoneal seeding	0	FOLFIRI	Capecitabine 1# bid +Irinotecan 100 mg/m2 q2wk	4	SD	PR	RECIST	3	A
14	Colon ca with lung and pelvic meta	0	FOLFOX+ Bevacizumab	Capecitabine 1# bid +Irinotecan 100 mg/m2 q2wk	5	PD	SD	Tumor marker > 50% decline	4	A
15	Breast ca with liver and abdomen LN meta	1	CAF, Docetaxel	Vinorelbine 30 mg p.o. weekly, Capecitabine 1# bid, Gemcitabine 800 mg/m2 q2wk	3	SD	PR	RECIST	4	A
16	Breast ca with bone meta	0	Tamoxifen	Vinorelbine 30 mg p.o. weekly, Capecitabine 1# bid, Gemcitabine 800 mg/m2 q2wk	5	PD	SD	Tumor marker > 50% decline	8	A
17	Breast ca with chest wall recurrence	0	CAF, Docetaxel	Vinorelbine 30 mg p.o. weekly, Capecitabine 1# bid, Gemcitabine 800 mg/m2 q2wk	4	SD	PR	RECIST	12	A
18	Breast ca with bone and chest wall recurrence	1	RT, CAF, Docetaxel	Vinorelbine 30 mg p.o. weekly, Capecitabine 1# bid, Gemcitabine 800 mg/m2 q2wk	2	PD	SD	RECIST	5	A
19	Phylloides tumor with lung meta	0	CAF	Cyclophosphamide (50)1# qod, Etoposide(50) 1# qod, Gemcitabine 1400 mg q2wk	3	SD	PR	RECIST	12	D
20	Fibrosarcoma with lung meta	0	—	Cyclophosphamide (50)1# qod, Etoposide(50) 1# qod, Gemcitabine 1400 mg q2wk	3	SD	PR	RECIST	6	D
21	Sarcoma, nonspecific with LN meta	0	—	Cyclophosphamide (50)1# qod, Etoposide(50) 1# qod, Gemcitabine 1400 mg q2wk	2	PD	PD	RECIST	3	D
22	Leiomyosarcoma of uterus with pelvic recurrence	1	—	Cyclophosphamide (50)1# qod, Etoposide(50) 1# qod, Gemcitabine 1400 mg q2wk	2	PD	PD	RECIST	4	D
23	Buccal ca, local recurrence	1	CCRT	Cyclophosphamide 50 mg qd, Methotrexate 50 mg q2wk, Tegafur and Uracil (UFT) 1# tid cisplatin 30/m2 q2wk	3	PD	SD	RECIST	6	D
24	Gingival ca, with lung meta	1	—	Cyclophosphamide 50 mg qd, Methotrexate 50 mg q2wk, Tegafur and Uracil (UFT) 1# tid	2	SD	PR	RECIST	8	A
25	Parotid gland ca, adenoid cystic carcinoma with multiple meta	1	Doxorubicin 50/m2 + cisplatin 60/m2 q3w	Cyclophosphamide 50 mg qd, cisplatin 30/m2 q2wkMethotrexate 50 mg q2wk, Tegafur and Uracil (UFT) 1# tid cisplatin 30/m2 q2wk	3	PD	PD	RECIST	3	A

Abbreviations: Ca, cancer; meta, metastasis; bid, twice a day; tid, three times a day; qd, every day; qod, every other day; q2wk, every 2 weeks; LN, lymph node(s); CCRT, concomitant chemoradiotherapy; TKI, tyrosine kinase inhibitor; RT, radiotherapy; FOLFIRI, Irinotecan with fluorouracil and folinic acid; FOLFOX, oxaliplatin with fluorouracil and folinic acid; CAF, 5-fluorouracil, doxorubicin, cyclophosphamide.